TABLE 1.
Characteristics of Included Participants by Cancer Status at the Time of the First Fatigability Assessment
| Characteristic | No. of Participants (%) | Pc | ||
|---|---|---|---|---|
|
| ||||
| History of Cancer | No History of Cancer, N = 1331 | |||
|
| ||||
| Prevalent, N = 248a | Incident, N = 86b | |||
| Age, y | ||||
| Mean ± SD | 73.6 ± 9.9 | 74.1 ± 12.1 | 69.3 ± 15.6 | |
| ≥65 | 52 (21.0) | 20 (23.3) | 486 (36.5) | < .001 |
| >65 | 196 (79.0) | 66 (76.7) | 845 (63.5) | |
| Sex | ||||
| Men | 152 (61.3) | 56 (65.1) | 597 (44.9) | < .001 |
| Women | 96 (38.7) | 30 (34.9) | 734 (55.2) | |
| BMI: Mean ± SD, kg/m2 | 26.9 ± 4.7 | 27.4 ± 4.3 | 27.4 ± 5.3 | |
| Race | .5 | |||
| Caucasian | 206 (83.1) | 59 (68.6) | 922 (69.3) | |
| Other | 42 (16.9) | 27 (31.4) | 409 (30.7) | .002 |
| Smoking statusd | ||||
| Ever smoker | 127 (51.4) | 45 (53.6) | 542 (41.1) | |
| Never smoker | 120 (48.6) | 39 (46.4) | 776 (58.9) | < .001 |
| Comorbidities | ||||
| Mean no. ± SD | 1.4 ± 1.2 | 1.4 ± 1.3 | 1.2 ± 1.3 | |
| Cardiovascular disease | 50 (20.2) | 13 (15.1) | 174 (13.1) | < .001 |
| Hypertension | 117 (47.2) | 41 (47.7) | 541 (40.7) | < .001 |
| Pulmonary disease | 14 (5.6) | 3 (3.5) | 68 (5.1) | .02 |
| Diabetes | 23 (9.3) | 9 (10.5) | 103 (7.7) | .67 |
| Stroke | 12 (4.8) | 6 (7.0) | 64 (4.8) | .27 |
| Liver disease | 2 (0.81) | 4 (4.6) | 13 (0.9) | .02 |
| Kidney disease | 15 (6.0) | 8 (9.3) | 64 (4.8) | .72 |
| Peripheral neuropathy | 28 (11.3) | 6 (7.0) | 149 (11.2) | .02 |
| Arthritis | 86 (34.7) | 32 (37.2) | 3 (0.7) | .03 |
| Depression | 44 (17.9) | 17 (20.7) | 247 (18.7) | .32 |
Abbreviations: BMI, body mass index; SD, standard deviation.
a
These were participants who had a diagnosis of cancer at the time of the index visit.
b
These were participants who had a diagnosis of cancer after the index visit (incident).
c
Differences are between patients who had any history of cancer versus those without a history of cancer.
d
Numbers shown for participants who reported smoking status- missing smoking status in 3 participants with a history of cancer and 13 cancer-free participants.